Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06400121 · ClinicalTrials.gov registry record · Phase 2

Apimostinel + Automated Neurocognitive Training for Depression

A Phase 2 study of Depression, sponsored by Rebecca Price.

Recruiting
Registry status
Phase 2
Development phase
150
Enrollment target
1
Study location

NCT06400121 is a Phase 2 study of Depression that is actively recruiting participants, run by Rebecca Price. The registered enrollment target is 150 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06400121, a Phase 2 study of Depression, is actively recruiting participants, sponsored by Rebecca Price.

RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with minimal side effects or safety concerns. Cognitive Training (CT) is a digital intervention that has shown promise in extending the durability of another similar drug (ketamine). This randomized controlled trial will test the efficacy and safety of apimostinel (vs. placebo) for the acute treatment of depression, and will test the potential of CT to enhance and/or extend the durability of apimostinel's antidepressant effect.

Conditions Studied

Interventions

  • BEHAVIORAL Sham Training
  • BEHAVIORAL Cognitive Training
  • DRUG Apimostinel Infusion, Intravenous
  • DRUG Isotonic Solution, Intravenous

Study Locations (1)

Pennsylvania

  • Western Psychiatric Institute and Clinic - Pittsburgh

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-10-28
Est. Completion 2029-12-01
Phase Phase 2

Sponsor

Rebecca Price

7 total trials

What the Registry Record Tells You About NCT06400121

The ClinicalTrials.gov registry entry for NCT06400121 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (81% lower). The listed sponsor is Rebecca Price, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 4 interventions - of which Sham Training is the first listed.

NCT06400121 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06400121 about?

NCT06400121 is a clinical study titled "Apimostinel + Automated Neurocognitive Training for Depression". Apimostinel shows initial promise as a novel rapid-acting antidepressant medication with minimal side effects or safety concerns. Cognitive Training (CT) is a digital intervention that has shown promise in extending the durability of another similar drug (ketamine). This randomized controlled trial ...

What is the current status of trial NCT06400121?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-10-28. Estimated completion is 2029-12-01.

What conditions does trial NCT06400121 study?

This clinical trial studies the following conditions: Depression.

What interventions are being tested in trial NCT06400121?

The interventions under investigation include: Sham Training (BEHAVIORAL), Cognitive Training (BEHAVIORAL), Apimostinel Infusion, Intravenous (DRUG), Isotonic Solution, Intravenous (DRUG).

Who is sponsoring clinical trial NCT06400121?

This trial is sponsored by Rebecca Price, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06400121 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.